Literature DB >> 9193313

Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

N Blackwell, J Hayllar, G Kelly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9193313      PMCID： PMC2126834     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

Authors:  I F Comaish; C Gorman; N R Galloway
Journal:  BMJ       Date:  2000-05-20

2.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

3.  Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers.

Authors:  I Nousiainen; R Kälviäinen; M Mäntyjärvi
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

4.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

Review 5.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

Authors:  V Ponjavic; S Andréasson
Journal:  Doc Ophthalmol       Date:  2001-01       Impact factor: 2.379

7.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

8.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

9.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

10.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.